To assess whether nelarabine directly affected PI3K/AKT and MEK/ERK1/2 signaling pathways, we have treated T-ALL resistant to nelarabine cells with selective inhibitors of these two axes. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.